Carboplatin, French Formula

Obese correction not included

The French Formula estimates carboplatin clearance using patient morphologic and biologic characteristics to individualize dosing.

Gender
Female+0.686Male+1
kglbs
mg/dLumol/L
mg/mL*min
yo

Indications for Use

Used to individualize carboplatin dosing based on renal function to achieve a target AUC. Indicated for ovarian cancer, endometrial cancer, triple‑negative breast cancer, small‑cell and non‑small‑cell lung cancer, testicular cancer, and mesothelioma where carboplatin is part of standard regimens. Clinically useful to optimize efficacy, limit thrombocytopenia, and avoid overdosing in renal impairment.

Insights & Cautions

Use GFR‑based AUC dosing (dose = AUC × [GFR + 25]), but ensure GFR is accurate: cystatin‑C–creatinine–combined eGFR is most precise in cancer patients and prevents carboplatin overdosing (10–20% with creatinine‑only eGFR) 1 [Level II evidence]. Avoid Cockcroft‑Gault due to major under‑ or overdosing risk 2 [Level II evidence]. In extremes of weight or unstable renal function, use non‑indexed eGFR or measured GFR per KDIGO 3 [Level I evidence].